Pharmaceuticals News

The pharmaceuticals news email from Wiser has been specifically designed for anyone with an interest in the industry. This includes medical practitioners, investors and those involved in research and development. By its very nature, the pharmaceutical industry is subject to constant change. It is a research-driven industry with companies spending much of their revenues developing new medicines and vaccines. As a result patients are able to get new and more effective treatments. This is helping to increase the life expectancy of individuals in most countries. But there are challenges. The costs of the research and development can be large which puts up the price of drugs, while governments and the medical industry argue to try to keep prices as low as possible. The industry also faces challenges from alternatives, both legal (through generic drugs) and illegal (through black market economies). To follow the latest developments in this industry you should sign up for the pharmaceuticals news email from Wiser. It is the best way to find must-read articles on the topic from around the web.

Recent Pharmaceuticals News Coverage
 
Your Weekly Recommendations Wednesday, March 29, 2017
 
Recommended for you
INC Research: A Top-Tier CRO At A Low-Tier Price
Seeking Alpha • Boris Marjanovic
Roche MS drug Ocrevus approved by FDA after 3-month delay
Reuters
A push to get more California minorities into clinical trials
KPCC • Rebecca Plevin
Cyclacel Pharmaceuticals' (CYCC) CEO Spiro Rombotis on Q4 2016 Results - Earnings Call Transcript
Seeking Alpha
Global Drugmakers Poised for Windfall of Approvals in China
Bloomberg
Vertex Pharma shares jump more than 20% on cystic fibrosis study results
MarketWatch • Wallacewitkowski
FDA User Fee Hearings Picking Up Steam on Capitol Hill
The National Law Review • Cohn, Ferris, Glovsky, Levin, Mintz, P.C, Popeo
FDA OKs Eczema Injection; Owners Regeneron, Sanofi Set $37K Price
Xconomy • Alex Lash
Regeneron stock declines 1.5% on new drug’s $37,000-a-year price tag
MarketWatch • Emmacourt
Severe Eczema Drug Is Approved by F.D.A.; Price Tag Is $37,000 a Year
The New York Times • Katie Thomas
 
Recommended for You
Accounting, Pharmaceuticals
INC Research: A Top-Tier CRO At A Low-Tier Price
Seeking AlphaBoris Marjanovic
Summary INC Research is uniquely positioned to deliver low-teen growth on the back of favorable R&D outsourcing trends and acquisitions. With better-than-industry margins and significant competitive advantages, particularly in the complex trial design arena, the outlook for the company is bright. Shares...
Share
Biotechnology, Novartis AG
Roche MS drug Ocrevus approved by FDA after 3-month delay
Reuters
March 28 (Reuters) - The U.S. Food and Drug Administration (FDA) on Tuesday approved Roche Holding AG's multiple sclerosis (MS) drug Ocrevus, putting the potential blockbuster drug back on track after a delay by regulators over manufacturing issues.
Share
Epidemiology, Pharmaceuticals
A push to get more California minorities into clinical trials
KPCCRebecca Plevin
; Credit: Adam Berry/Getty Images Rebecca PlevinSome ethnic groups are more prone to certain diseases. Some groups of people respond differently to various drugs. But most participants in clinical trials are white, even though people of racial and ethnic minorities make up...
Share
Cancer, Financial Regulatory Bodies
Cyclacel Pharmaceuticals' (CYCC) CEO Spiro Rombotis on Q4 2016 Results - Earnings Call Transcript
Seeking Alpha
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Q4 2016 Earnings Conference Call March 28, 2017 04:30 PM ET Executives Alex Fudukidis - Russo Partners Spiro Rombotis - CEO Paul McBarron - COO Judy Chiao - VP Clinical Development & Regulatory Affairs Analysts Operator Good afternoon...
Share
Biotechnology, Cancer
Global Drugmakers Poised for Windfall of Approvals in China
Bloomberg
China is starting to approve new medicines at an unprecedented pace this year, opening the floodgates for innovative therapies to enter the country and potentially turbo-charging growth for multinationals in the world’s second-largest pharmaceutical market. Over the past few weeks, the China...
Share
Finance, Pharmaceuticals
Vertex Pharma shares jump more than 20% on cystic fibrosis study results
MarketWatchWallacewitkowski
Vertex Pharmaceuticals Inc. shares surged in the extended session Tuesday after the biotech drug maker said its cystic fibrosis treatment met endpoints in two late-stage clinical studies. Vertex shares rose 6.3% to $95.30 after hours, before being halted. As after-hours trading resumed,...
Share
Legal Services, Pharmaceuticals
FDA User Fee Hearings Picking Up Steam on Capitol Hill
The National Law ReviewCohn, Ferris, Glovsky, Levin, Mintz, P.C, Popeo
As we noted previously in our introductory blog post on the 2017 User Fee Act (UFA) reauthorization process, the first UFA hearing on Capitol Hill was convened on March 2, 2017 by the House Energy & Commerce Committee’s (E&C) Subcommittee on Health....
Share
Asthma, Pfizer, Inc.
FDA OKs Eczema Injection; Owners Regeneron, Sanofi Set $37K Price
XconomyAlex Lash
New York — For the more severe cases of eczema—inflamed skin that can range from annoying dry patches to painful swelling, oozing, and cracking—there’s a new injectable medicine on the market that will cost tens of thousands of dollars a year. The...
Share
Finance, Pharmaceuticals
Regeneron stock declines 1.5% on new drug’s $37,000-a-year price tag
MarketWatchEmmacourt
Regeneron shares declined 1.5% midday Tuesday after the company announced the Food and Drug Administration approval of its atopic dermatitis drug with Sanofi SA. The drug, Dupixent, is the first treatment for those with the inflammatory disease who haven’t been helped by...
Share
Finance, Health Care Industry
Severe Eczema Drug Is Approved by F.D.A.; Price Tag Is $37,000 a Year
The New York TimesKatie Thomas
The Food and Drug Administration approved on Tuesday an expensive drug to treat people with a serious form of eczema, a potential breakthrough for people who have suffered for years without relief. But it will not come cheap. The drug, to be...
Share